Can prognostic scoring systems for chronic myeloid leukemia as established in adults be applied to pediatric patients?

Annals of Hematology

Volumn 94, Issue 8, 2015, Pages 1363-1371

  Salas, David Gurrea ^a   Glauche, Ingmar ^b   Tauer, Josephine T ^a   Thiede, Christian ^a   Suttorp, Meinolf ^a  

^a UNIVERSITY HOSPITAL CARL GUSTAV CARUS   (Germany)

^b DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

Author keywords

Children; CML; EUTOS; Hasford; Score; Sokal

Indexed keywords

BCR ABL1 PROTEIN; IMATINIB; TUMOR MARKER; UNCLASSIFIED DRUG;

ARTICLE; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER PROGNOSIS; CANCER REGISTRY; CHRONIC MYELOID LEUKEMIA; EUTOS SCORE; FEMALE; HASFORD SCORE; HIGH RISK POPULATION; HUMAN; LOW RISK PATIENT; MAJOR CLINICAL STUDY; MALE; PATIENT CODING; PRIORITY JOURNAL; PROGNOSTIC ASSESSMENT; SCORING SYSTEM; SOKAL SCORE; TREATMENT OUTCOME; TREATMENT RESPONSE; ADOLESCENT; ADULT; AGE; CHILD; COHORT ANALYSIS; INFANT; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; NEWBORN; PRESCHOOL CHILD; PROGNOSIS; REGISTER; SEVERITY OF ILLNESS INDEX; STANDARDS;

ADOLESCENT; ADULT; AGE FACTORS; CHILD; CHILD, PRESCHOOL; COHORT STUDIES; FEMALE; HUMANS; INFANT; INFANT, NEWBORN; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MALE; PROGNOSIS; REGISTRIES; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 84973254800     PISSN: 09395555     EISSN: 14320584     Source Type: Journal    
DOI: 10.1007/s00277-015-2367-2     Document Type: Article

References (60)

1. Altman AJ (2000) Chronic leukemias of childhood. In: Pizzo PA, Poplack DG (eds) Principles and practice of pediatric oncology. Lippincot Williams & Wilkins (LWW) pp 591-614
2. Andolina JR, Neudorf SM, Corey SJ (2012) How I treat childhood CML. Blood 119(8):1821-1830
3. Baccarani M (2010) Calculation of relative risk of CML patients http://www.leukemia-net.org/content/leukemias/cml/cml_score/index_eng.html
4. Baccarani M, Pileri S, Steegmann JL et al (2012) Chronic myeloid leukemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 23(S7):72-77
5. Breccia M, Finsinger P, Loglisci G et al (2012) The EUTOS score identifies chronic myeloid leukemia patients treated with imatinib first or second line. Leuk Res 36(9):e209-e210
6. Castagneti F, Gugliotta G, Palandri F et al (2012) EUTOS score is predictive for survival and outcome of patients with early chronic phase chronic myeloid leukemia treated with nilotinib-base regimens. Haematologica 97(Suppl. 1, abstract #193):76
7. Castro-Malaspina H, Schaison G, Breire J et al (1983) Philadelphia chromosome-positive chronic myelocytic leukemia in children. Survival and prognostic factors. Cancer 52(4):721-727
8. Cerrano M, Crisà E, Pregno P et al (2013) Excellent therapeutic results achieved in chronic myeloid leukemia patients with frontline imatinib and early treatment modifications in suboptimal responders: a retrospective study on 91 unselected patients. Am J Hematol 88(10):838-842
9. Cortes J, Kantarjian H (2003) Advanced-phase chronic myeloid leukemia. Semin Hematol 40(1):79-86
10. Cwynarski K, Roberts IA, Iacobelli S et al (2003) Stem cell transplantation for chronic myeloid leukemia in children. Blood 102(4): 1224-1231
11. De la Fuente J, Baruchel A, Biondi A, on behalf of the International BFMGroup Study Group ChronicMyeloid Leukaemia Committee et al (2014) How I manage CML in children. Guidelines for the management of chronic myeloid leukaemia in children and young people up to the age of 18 years. Br J Haematol 167(1):33-47
12. Druker BJ, Guilhot F, O’Brien SG et al (2006) Five-year follow-up of patients receiving imatinib for chronicmyeloid leukemia. N Engl J Med 355(23):2408-2417
13. Faderl S, Talpaz M, Estrov Z et al (1999) The biology of chronic myeloid leukemia. N Engl J Med 341(3):164-172
14. Giles FJ, Coutre PD, Pinilla-Ibarz J et al (2013) Nilotinib in imatinib-resistant or imatinib-intolerant patients with chronic myeloid leukemia in chronic phase: 48-month follow, results of a phase II study. Leukemia 27(1):107-112
15. Goldman JM (2007) How I treat chronic myeloid leukemia in the imatinib era. Blood 110(8):2828-2837
16. Goldman JM, Majhail NS, Klein JP et al (2010) Relapse and late mortality in 5-year survivors of myeloablative allogeneic hematopoietic cell transplantation for chronic myeloid leukemia in first chronic phase. J Clin Oncol 28(11):1888-1895
17. Gratwohl A, Brand R, Apperley J et al (2006) Allogeneic hematopoietic stem cell transplantation for chronic myeloid leukemia in Europe 2006: transplant activity, long-term data and current results. An analysis by the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation (EMBT). Haematologica 91(4):513-521
18. Gugliotta G, Castagnetti F, Palandri F et al (2011) Frontline imatinib treatment of chronic myeloid leukemia: no impact of age on outcome, a survey by the GIMEMA CML Working Party. Blood 117(21):5591-5599
19. Hanfstein B, Müller MC, Hehlmann R et al (2012) Early molecular and cytogenetic response is predictive for long-term progressionfree and overall survival in chronic myeloid leukemia (CML). Leukemia 26(9):2096-2102
20. Hasford J, Pfirmann M, Hehlman R et al (1998) A new prognostic score for survival of patients with chronic myeloid leukemia treated with interferon alpha. Writing Committee for the collaborative CML Prognostic Factors Project Group. J Natl Cancer Inst 90(11):850-858
21. Hasford J, Baccarani M, Hoffman V et al (2011) Predicting complete cytogenetic response and subsequent progression-free survival in 2060 patients with CML on imatinib treatment: the EUTOS score. Blood 118(3):686-692
22. Hijiya N, Millot F, Suttorp M (2015) Chronic myeloid leukemia in children: clinical findings, management, and unanswered questions. Pediatr Clin N Am 62:107-119
23. Hochhaus A (2008) Prognostic factors in chronicmyeloid leukemia (CML). Onkologie 31(11):576-578
24. Hochhaus A (2011) Educational session: managing chronic myeloid leukemia as a chronic disease. Hematol AmSoc Hematol Educ Program 2011:128-135
25. Hochhaus A, O’Brien SG, Guilhot F et al (2009) Six-year followup of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia. Leukemia 23(6):1054-1061
26. Hoffman VS, Baccarani M, Lindoerfer D et al (2013) The EUTOS prognostic score: review and validation in 1288 patients with CML treated frontline with imatinib. Leukemia 27(10):2016-2022
27. Hughes T, Hochhaus A, Brandford S et al (2010) Long-term prognostic significance of early molecular response to imatinib in newly diagnosed chronic myeloid leukemia: an analysis from the International Randomized Study of Interferon and STI571 (IRIS). Blood 116(19):3758-3765
28. Jabbour E, Cortes J, Kantarjian MH et al (2006) Allogeneic stem cell transplantation for patients with chronic myeloid leukemia and acute lymphocytic leukemia after Bcr-Abl kinase mutation-related imatinib failure. Blood 108(4):1421-1423
29. Jabbour E, Cortes J, Nazha A et al (2012) EUTOS score is not predictive for survival and outcome in patients with early chronic phase of chronic myeloid leukemia treated with tyrosine kinase inhibitors: a single institution experience. Blood 119(19):4524-4526
30. Kalmanti L, Saussele S, Lauseker M et al (2014) Younger patients with chronic myeloid leukemia do well in spite of poor prognostic indicators: results from the randomized CML-study IV. Ann Hematol 93(1):71-80
31. Lakshmaiah KC, Bhise R, Purohit S et al (2012) Chronic myeloid leukemia in children and adolescents: results of treatment with imatinib mesylate. Leuk Lymphoma 53(12):2430-2433
32. Latagliata R, Isidori A, Breccia M et al (2013) Complete clearance of Ph+metaphases after 3 months is a very early indicator of good response to imatinib as front-line treatment in chronic myelogenous leukemia. Acta Haematol 129(2):126-134
33. Marin D, Ibrahim AR, Goldman JM (2011) European Treatment and Outcome Study (EUTOS) score for chronic myeloid leukemia still requires more confirmation. J Clin Oncol 29(29):3944-3945
34. Marin D, Ibrahim AR, Lucas C et al (2012) Assessment of BRCABL1 transcript levels at 3 months is the only requirement for predicting outcome for patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors. J Clin Oncol 30(3):232-238
35. Millot F, Traore P, Guilhot J et al (2005) Clinical and biological features at diagnosis in 40 children with chronic myeloid leukemia. Pediatrics 116(140):2004-2473
36. Millot F, Baruchel A, Guilhot J et al (2011) Imatinib is effective in children with previously treated chronic myeloid leukemia in early chronic phase: results of the French national phase IV trial. J Clin Oncol 29(20):2827-2832
37. Millot F, Guilhot J, Suttorp M et al (2014) The experience of the international registry for chronic myeloid leukemia (CML) in children and adolescents (I-CML-Ped Study): prognostic consideration. Blood 124 (21), ASH annual meeting abstract #521
38. Muramatsu H, Kojima S, Yoshimi A et al (2010) Outcome of 125 children with chronic myelogeneous leukemia who received transplants from unrelated donors: the Japan Marrow Donor Program. Biol Blood Marrow Transplant 16(2):231-238
39. National Comprehensive Cancer Network (NCCN) (2013) http://www.nccn.org/patients/guidelines/cml/index.html NCCN practical guidelines in oncology (NCCN Guidelines) (2013). Accessed 13 Sep 2013
40. Neelakantan P, Gerrard G, Lucas C et al (2013) Combining BCRABL1 transcript levels at 3 and 6 months in chronic myeloid leukemia: implications for early intervention strategies. Blood 121(14):2739-2742
41. O’Reilly RA (1998) Splenomegaly in 2505 patients in a large university medical center from 1913 to 1995. 1913 to 1962: 2056 patients. West J Med 169(2):78-87
42. Ohm L, Arvidsson I, Barbany G et al (2012) Early landmark analysis of imatinib treatment in CML chronic phase: less than 10 % BCR-ABL by FISH at 3 months associated with improved longterm clinical outcome. Am J Hematol 87(8):760-765
43. Oyekunle AA, Osho PO, Aneke JC et al (2012) The predictive value of the Sokal and Hasford scoring systems in chronic myeloid leukemia in the imatinib era. J Hematol Malign 2(2):25-32
44. Pemmaraju N, Kantarjian H, Shan J et al (2012) Analysis of outcomes in adolescents and young adults with chronic myelogenous leukemia treated with upfront tyrosine kinase inhibitor therapy. Haematologica 97(7):1029-1035
45. Raman GR, Nasaka S, Gundeti S et al (2014) Effectiveness in predicting response and outcome with three prognostic scoring systems in pediatric CML on upfront imatinib. Blood 124 (21), ASH annual meeting abstract #4549
46. Saglio G, Fava C (2012) Practical monitoring of chronic myelogenous leukemia: when to change treatment. J Natl Compr Cancer Netw 10(1):121-129
47. Sokal JE, Cox EB, Baccarani M et al (1984) Prognostic discrimination in “good-risk” chronic granulocytic leukemia. Blood 63(4): 789-799
48. Sokal JE, Baccarani M, Tura S et al (1985) Prognostic discrimination among younger patients with chronic granulocytic leukemia: relevance to bone marrow transplantation. Blood 66(6):1352-1357
49. Sokal JE, Baccarani M, Russo D et al (1988) Staging and prognosis in chronic myelogenous leukemia. Semin Hematol 25(1):49-61
50. Steegmann JL, Casado LF (2012) The new EUTOS score has prognostic value in the treatment of chronic myeloid leukemia (CML) outside clinical trials. Blood E-Letter published online January 27, 2012
51. Suttorp M (2006) Protocol for standardized diagnostic procedures, registration and treatment recommendations in children and adolescents with Philadelphia chromosome-positive chronic myeloid leukemia (CML). CML-paed-II Study. http://www.kinderkrebsinfo.de/sites/kinderkrebsinfo/content/e1676/e9032/e1758/e5368/download38391/ClinicalTrialProtocolCML-paed-IIStudyDocumentation,ECVger.pdf (2006). Accessed 13 Sep 2013
52. Suttorp M, Millot F (2010) Treatment of pediatric chronic myeloid leukemia in the year 2010: use of tyrosine kinase inhibitors and stem cell transplantation. Hematol Am Soc Hematol Edu Program 2010:368-376
53. Suttorp M, Claviez A, Bader P et al (2009) Allogeneic stem cell transplantation for pediatric and adolescent patients with CML: results from the prospective trial CML-paed-I. Klin Padiatr 221(6):351-357
54. Suttorp M, Yaniv I, Schultz KR (2011) Controversies in the treatment of CML in children and adolescents. TKIs versus BMT. Biol Blood Marrow Transplant 17(Suppl 1):S115-S122
55. Suttorp M, Eckardt T, Tauer JT et al (2012) Management of chronic myeloid leukemia in childhood. Curr HematolMalig Rep 7(2):116-124
56. Suttorp M, Glauche I, Gurrea Salas D et al (2013) Scoring systems for predicting outcome of chronic myeloid leukemia in adults are poorly informative in pediatric patients treated with imatinib (abstract). Blood 122(21):2725
57. Tanaka MF, Kantarjian H, Cortes J et al (2012) Treatment options for chronic myeloid leukemia. Expert Opin Pharmacother 13(6): 815-828
58. Trask PC, Mitra D, Iyer S et al (2012) Patterns and prognostic indicators of response toCML treatment in a multi-country medical record review study. Int J Hematol 95(5):535-544
59. Verbeek W, König H, Boehm J et al (2006) Continuous complete hematological and cytogenetic remission with molecular minimal residual disease 9 years after discontinuation of interferon-alpha in a patient with Philadelphia chromosome-positive chronic myeloid leukemia. Acta Haematol 115(1-2):109-112
60. Williams K, Thomson D, Seto I et al (2012) Standard 6: age groups for pediatric trials. Pediatrics 129(Suppl 3):S153-S160